The firm, founded in 2017 and based in Brussels, has a leadership team of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects. As a hands-on investor, Newton Biocapital supports promising start-up projects as well as neglected or undervalued late-stage projects, with the goal of mitigating risks and creating investor value. The firm is among the 8 VC firms certified by AMED in Japan to boost the pharma ecosystem and the only one with offices in Japan/Europe. Newton Biocapital's diversified team of experts and its presence in Japan/Europe enable the firm to identify and select the most promising companies based on the outstanding research ecosystem in these two regions. NBC provides investment opportunities that can help patients and society, as well as foster growth of the Japanese/European biotech ecosystems.